M
ore than 2 million new HIV infections occur annually worldwide, with about half in women (1) . Effective strategies to prevent HIV acquisition among women are urgently needed, yet studies of HIV preexposure prophylaxis (PrEP) in women have shown conflicting results. The Partners PrEP study, conducted in serodiscordant heterosexual couples in Africa, showed that PrEP containing tenofovir disoproxil fumarate (TDF) was associated with a 67% to 75% reduction in HIV infections overall and a 66% to 71% reduction in women (2) . The TDF2 study, conducted in sexually active heterosexual adults in Botswana, showed that TDFemtricitabine (FTC) was associated with a 62% reduction in HIV infections overall and a 49% reduction in women (3) . However, FEM-PrEP (Preexposure Prophylaxis Trial for HIV Prevention among African Women) and the VOICE (Vaginal and Oral Interventions to Control the Epidemic) study, both conducted exclusively in women, failed to demonstrate efficacy of oral TDFcontaining PrEP over placebo in reducing HIV infection, mainly due to suboptimal participant adherence to study drugs (4, 5) . In contrast, among men who have sex with men (MSM), PrEP with TDF-FTC was associated with a 44% reduction in HIV acquisition in the iPrEx (Preexposure Prophylaxis Initiative) study (6) and an 86% reduction in the IPERGAY (Intervention Pré ventive de l'Exposition aux Risques avec et pour les Gays) (7) and PROUD (8) studies.
Current guidelines recommend daily oral HIV PrEP for persons at "substantial" risk for HIV infection, including women (9 -11) . The only regimen currently approved by the U.S. Food and Drug Administration (FDA) is daily oral TDF-FTC, but tenofovir diphosphate drug concentrations are more than 100-fold lower in See also:
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the female genital tract than in the colorectal mucosa (12, 13) . Preexposure prophylaxis with TDF-FTC was associated with significantly more gastrointestinal adverse effects than placebo in women in FEM-PrEP (4) , and decreased renal function was significantly more common with TDF-containing regimens than with placebo in women in the Partners PrEP (2, 14) and VOICE (5) studies. Also, TDF-FTC was associated with a small but statistically significant loss of bone mineral density in men and women in some PrEP studies (3, 15, 16) . For these reasons, alternative PrEP regimens are needed.
Maraviroc (MVC) is a CCR5 antagonist HIV entry inhibitor that has been approved for treatment of HIV infection on the basis of randomized clinical trials in HIV-infected, treatment-experienced participants (only 11% of whom were women) (17) . Maraviroc is active against R5 (CCR5-tropic) HIV, which is associated with most acute HIV transmissions (18) , and it has additional favorable properties as HIV PrEP for women: Compared with plasma, it has a 2-to 3-fold higher concentration in cervicovaginal fluid, a 2-fold higher concentration in vaginal tissue (19) , and an 8-to 26-fold higher concentration in rectal tissue (20) . Maraviroc has no clinically relevant interactions with the oral contraceptives ethinylestradiol and levonorgestrel (21) . It is prescribed infrequently for HIV treatment (22) and does not select for drug resistance to recommended firstline antiretroviral drugs. Maraviroc was generally safe in HIV-infected persons for at least 5 years (23) and was associated with less bone loss than TDF in a comparative study of combination antiretroviral regimens in HIV-infected persons (24) . A 12-week pilot study of 126 HIV-uninfected participants with rheumatoid arthritis (81% women) hypothesized that MVC could prevent chemokine-induced CCR5 activation (and resultant tissue and joint destruction) and found that it was generally well-tolerated (25) . In a parallel study of U.S. MSM and transgender women who were at risk but were HIVuninfected, MVC-containing PrEP regimens were generally safe and tolerable compared with TDF-FTC (26) . In this study, we compared the safety and tolerability of MVC-containing HIV PrEP regimens versus TDF-FTC in U.S. women at risk for HIV infection.
METHODS
Design Overview
This was a prospective, randomized, multicenter study of 4 antiretroviral regimens used as PrEP in HIVuninfected women who were at risk for HIV infection. The primary objective was to assess the safety and tolerability of the regimens over 48 weeks. Secondary objectives included assessing adherence and incident HIV infections. The study was approved by the institutional review board at each participating site, and all participants provided written informed consent before data collection. The study was registered at ClinicalTrials .gov (NCT01505114). A parallel study that used the same protocol was conducted earlier in MSM (26) .
Setting and Participants
The study was conducted in the United States and Puerto Rico, with participants recruited from the communities of 12 clinical research sites. The study was sponsored by the Division of AIDS of the National Institutes of Health through the HIV Prevention Trials Network (HPTN) and was cosponsored by the AIDS Clinical Trials Group. Participants were enrolled from March 2013 to December 2014, and follow-up concluded in November 2015.
Participants were eligible if they were born female, were aged 18 years or older, and reported condomless vaginal or anal intercourse with at least 1 man with known HIV infection or unknown serostatus within 90 days before study entry. Eligible participants agreed to use 1 form of contraception (condom, diaphragm or cervical cap, intrauterine device, or hormonal) during and for 30 days after the study and had adequate baseline safety laboratory results, including a creatinine clearance of at least 70 mL/min (calculated with the Cockcroft-Gault equation) within 45 days of study entry, a negative serum or urine pregnancy test result within 48 hours, a nonreactive HIV antibody test (performed at the site with the local standard-of-care assay and subsequently confirmed at the HPTN Laboratory Center 
Randomization and Interventions
Eligible participants were enrolled and randomly assigned with equal probability to receive 1 of 4 regimens: MVC (Selzentry, ViiV Healthcare), MVC plus FTC (Emtriva, Gilead Sciences), MVC plus TDF (Viread, Gilead Sciences), or TDF plus FTC (control). Doses were 300 mg for MVC, 200 mg for FTC, and 300 mg for TDF. The study regimen comprised a total of 3 pills that included matching placebos and were taken together orally once per day.
The computerized randomization method was developed, implemented, and monitored by the Statistical Center for HIV/AIDS Research and Prevention (Fred Hutchinson Cancer Research Center, Seattle, Washington) and was stratified by site using block randomization with a block size of 12, such that approximately equal numbers of participants were assigned to each group within each site. Site staff requested the randomization, and the site pharmacist received the randomized regimen assignments. All other site staff and study participants were blinded to randomized assignment until completion of follow-up.
Outcomes and Follow-up
The primary safety outcome was grade 3 (severe) and 4 (life-threatening) adverse events, as assessed (27) . The primary tolerability outcome was time to permanent discontinuation of the study regimen through 48 weeks of follow-up. Secondary outcomes included adherence (assessed by detectable plasma drug concentrations) and incident HIV infections (assessed by laboratory testing). After enrollment and randomization, participants were seen at weeks 2, 4, and 8 and then every 8 weeks through week 48. Regimens were discontinued at week 48, and a final visit was conducted at week 49. At each visit, an interval history, a targeted physical examination, safety laboratory tests (including a serum or urine pregnancy test), and site-standard risk reduction counseling were conducted; blood plasma was stored for drug concentration measurements; participants completed an adherence questionnaire; and study drugs and condoms were dispensed. Pre-post counseling and testing for HIV were conducted at each visit and whenever HIV infection was suspected. Adherence support was provided at each visit through semistructured, counselorguided discussions encouraging participant-centered problem-solving strategies.
Testing for sexually transmitted infections (STIs) (nucleic acid testing of cervical and rectal swabs and urine for chlamydia and gonorrhea, and serologic tests for syphilis) was done at study entry, week 16 or 24, and week 40 or 48 and whenever a participant reported symptoms suggestive of an STI; those with positive results continued use of study drugs and were referred for treatment. Participants were evaluated at each visit for HIV exposure, and those who requested PEP were referred locally. If the participant started PEP, they were instructed to hold study medications and undergo repeated HIV testing at least 14 days after completing PEP; if they were HIV-negative, they could resume their study regimen. Each site was required to have centrally approved, standard operating procedures for data management and quality assurance in place before study initiation.
Specialized testing and quality assurance, including HIV testing and confirmation of seroconversion, were performed at the HPTN Laboratory Center. Antiretroviral drug concentration testing was performed on plasma samples collected from participants at weeks 24 and 48. Laboratory personnel were unblinded to regimen assignment and tested samples for the assigned study drugs only. Concentrations of MVC, FTC, and tenofovir (TFV) were quantified via validated liquid chromatography tandem-mass spectrometric methods, with assay limits of quantification of 0.5 ng/mL for MVC Two participants were randomly assigned but never started their study regimen (1 in the MVC-only group who declined further participation and 1 in the MVC-TDF group who could not be contacted). FTC = emtricitabine; MVC = maraviroc; TDF = tenofovir disoproxil fumarate.
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and 0.3 ng/mL for FTC and TFV (28, 29) . Quantitative drug concentrations were reported and then designated as detectable or undetectable on the basis of assay-specific lower limits of quantification. In addition, drug concentrations were assessed in a subset of participants randomly assigned to TDF-or FTC-containing regimens who participated in a substudy (n = 32) and were compared with established adherence benchmarks based on directly observed dosing and a 90% sensitivity threshold for each adherence stratum (30) . Assays were validated in accordance with FDA Guidance for Industry (bioanalytical method validation recommendations) and were reviewed by the National Institutes of Health-supported Clinical Pharmacology Quality Assurance Program. Biannual external proficiency testing was also performed.
Statistical Analysis
The planned enrollment was 200 participants (50 per group), with an assumed rate of loss to follow-up of 5%. The length of the study was estimated at 2 years, with 9 months for accrual and 12-month follow-up of each participant. The sample size was selected to provide estimates for the true value of the safety end point (occurrence of grade 3 or 4 adverse events through 48 weeks) and a reasonable power to detect differences between groups for the tolerability end point (time to permanent discontinuation of the regimen). With 50 participants per group, if the observed adverse event rate was 20%, the estimate would have a 95% CI of 9% to 31%. The power to detect differences for the tolerability end point was 80% for TDF-FTC versus each of the 3 MVC-containing groups with a true hazard ratio of 2.8 and an incidence rate of 30%.
Primary data analysis was performed for all enrolled participants according to their original randomized assignment. The rates of grade 3 and 4 adverse events per person-year of observation (number of events per year) were summarized and compared between any 2 groups. Kaplan-Meier estimates were calculated to summarize the distribution of permanent discontinuation of the regimen.
Summary statistics were calculated as proportions, means or medians, or event rates (in person-years) depending on the variable being binary, continuous, or count data, respectively. For all statistics except medians (for which interquartile ranges were calculated), associated 95% CIs were calculated based on the underlying distribution being binomial, normal, or Poisson, respectively. Incidence of HIV infection was calculated using the exact method for Poisson counts. The study was reviewed biannually by an independent study monitoring committee of the HPTN. Phase
Role of the Funding Source
The Division of AIDS of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health funded the study. Gilead Sciences and ViiV Healthcare supplied study drugs. Representatives from the pharmaceutical companies served on the protocol team but did not contribute to final study interpretation. The investigators designed the study; collected, analyzed, and interpreted the data; wrote the manuscript; and made the decision to submit the manuscript for publication with input from the protocol team. The corresponding author had full access to the data and made the final decision to submit the manuscript.
RESULTS
Study Population
A total of 188 participants were enrolled in the study, with similar enrollment across the 12 sites, and were randomly assigned to 1 of the 4 study regimens ( Figure 1) ; all but 2 started use of study drugs. All participants were female at birth, and the median age was 35 years ( Table 1) . Sixty-five percent of participants were black, 17% were Latina (of any race), 27% were white, and 8% were of another race or ethnicity. Demographic characteristics were balanced among the study groups. During screening, before enrollment, 7 (4%) participants were diagnosed with STIs (3 [2%] with chlamydia and 4 [2%] with syphilis).
Study Disposition
Of 188 participants who were randomly assigned, 160 (85%) completed follow-up, 20 (11%) withdrew from the study early, and 8 (4%) were lost to follow-up ( Figure 1) . The most common reasons for withdrawing from the study early were declining further participation (n = 8) and inability to adhere to the visit schedule (n = 5). There was 1 death from suicide in the MVC-TDF group, which was judged not to be related to study drugs. Thirty-six (19%) participants permanently discontinued use of study drugs before week 48; of these, 3 also discontinued study participation and 33 completed follow-up. The most common reasons for early discontinuation of the regimen were participant request (n = 16) and pregnancy (n = 9). In total, 34% of participants stopped use of study drugs by week 48. There was no difference among groups in the proportion of participants who permanently discontinued use of study drugs ( Figure 2 ). ͉͉ These events were predetermined to be of interest given prior reports of toxicities associated with the study medications. All were grade 2 except for 2 occurrences of grade 3 hypophosphatemia and 1 occurrence of grade 3 weight loss.
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Among participants with available plasma specimens across the 4 study groups, all drugs in the regimen were detected in 65% (91 of 141) at week 24 and 60% (75 of 126) at week 48, without significant differences among groups. Among a subset of women who had detectable drug concentrations (n = 32), more than 90% had concentrations consistent with daily adherence (30), without differences between study regimens or time (week 24 or 48). The MVC-only group was not assessed because MVC concentration benchmarks for adherence have not been established. In an intention-to-treat analysis (where missing values were considered undetectable), 48% (91 of 188) of participants at week 24 and 40% (75 of 188) at week 48 had detectable drug concentrations. Participants reported that they took a median of 94% and 92% of their study medications as recommended at weeks 24 and 48, respectively, with no differences among groups.
Adverse Events and HIV Acquisition
Thirty-five (19%) participants had a total of 48 grade 3 or 4 adverse events. There was no difference among groups in occurrence or rates of these events, and fewer than 25% were judged to be related to study drugs ( Table 2 and Appendix Table) . Rates of preselected gastrointestinal and renal grade 2 to 4 adverse events also were similar among regimens ( Table 2 and   Appendix Table) . Overall creatinine clearance decreased by a median of 3.3% from baseline to week 48, with no differences among groups. Among 16 pregnancies occurring during the study, there were 2 congenital abnormalities (Table 3) . During follow-up, 4 (2%) participants were diagnosed with STIs (1 [1%] with gonorrhea and 3 [2%] with chlamydia). One participant reported using HIV PEP. No participant acquired HIV infection during the study; the overall annualized incidence of HIV infection was 0% (95% CI, 0% to 2.3%).
DISCUSSION
In this phase 2, prospective, randomized, controlled, double-blinded, multicenter 48-week study of U.S. women at risk for HIV infection, we showed that MVC-containing antiretroviral regimens used as PrEP were generally safe and well-tolerated compared with TDF-FTC. The number of participants discontinuing use of study medications and time to discontinuation did not differ among regimens, and the rates of grade 3 and 4 and specific adverse events of interest, including gastrointestinal adverse effects, hypophosphatemia, and increased creatinine levels, were similar among the study groups. Our team reported similar safety and tol- About one third of women in this study discontinued use of study drugs by week 48, including 11% who withdrew from the study early, 4% who were lost to follow-up, and 19% who discontinued use prematurely (9 of whom did so because of pregnancy, as required by the protocol). The reasons for this relatively high discontinuation rate are likely multifactorial and include pregnancy, drug toxicities, pill burden, and perceived low HIV risk. A total of 19% of women had grade 3 or 4 adverse events while using study drugs, although only one quarter of the grade 3 events and none of the grade 4 events were judged to be related to study drugs. Women in the United States who practice condomless sex and live in neighborhoods with high HIV prevalence have an annual incidence rate of 0.32% and may benefit from effective HIV PrEP regimens (9, 31) . However, such regimens must be safe, well-tolerated, and perceived as necessary for women to use them consistently.
Among 16 pregnancies occurring during the study, there were 2 congenital abnormalities ( Table 3) . The most recent interim report from the Antiretroviral Pregnancy Registry states that the rate of birth defects in women exposed to antiretroviral drugs is 2.8 per 100 live births, which is not significantly different from the rate in the general population (32) . In addition, the report states that sufficient numbers of first-trimester exposures have been monitored to detect at least a 1.5-fold increase in risk for birth defects with many antiretroviral drugs, including TDF and FTC, and that no such increases have been detected (32) . There currently are not enough reports of MVC to discern whether there is an increased risk in pregnancy compared with other antiretroviral drugs. Animal reproduction studies found no evidence of adverse developmental outcomes with MVC, and the drug is labeled as FDA pregnancy category B (33).
Adherence is critical for efficacy of HIV PrEP (34, 35) . Adherence to study medications in FEM-PrEP and the VOICE study, which were conducted when HIV PrEP was an unproven strategy for women, was less than 30% to 40% (4, 5). In our study, which was conducted after studies reported efficacy of PrEP, study drugs were detected in 60% to 65% of plasma samples tested; the rate of premature discontinuation of study regimens (34%) affects this estimate. Although a detectable TFV or FTC concentration indicates only 1 or more doses taken in the prior week, in a subset of women with detectable drug levels, more than 90% had TFV or FTC concentrations consistent with daily adherence in the prior week, which suggests adherence consistent with a protective effect against HIV acquisition (30) . Tenofovir diphosphate drug concentrations are more than 100-fold lower in the female genital tract than in the colorectal mucosa (12, 13) . A model predicted that 85% adherence to TDF-FTC (≥6 daily doses per week) would be necessary for women to achieve target exposure in the female genital tract versus only 28% adherence (≥2 daily doses per week) to achieve target exposure in colorectal tissue (36 -38) . Suboptimal adherence compromises the efficacy of TDF-FTC, particularly in women. Further investigation of alternative agents with more favorable pharmacokinetics for HIV PrEP regimens in women is needed.
This phase 2 safety study was not designed to assess the efficacy of the study regimens in preventing HIV infection; we recruited participants who were "at risk" for infection rather than necessarily at "high risk." Although no participant acquired HIV in our study, whether the study regimens prevented HIV acquisition or participants were at low risk for infection (or both) is unclear. The low number of other new STIs during this 48-week study (n = 4) and the fact that only 1 participant reported PEP use suggest that participants were at low risk for acquiring HIV during the study. Of note, in our study testing the same regimens in 406 MSM, 5 (26) . We cannot draw conclusions about the efficacy of MVCcontaining PrEP regimens from these studies. This study has strengths and limitations. It was a comparative study of HIV PrEP conducted in U.S. women who were at risk for HIV infection. Our study population was racially and ethnically similar to that of women living with HIV infection in the United States, with significant representation of women of color. The active-controlled design ensured that every participant received an antiretroviral drug regimen (there was no all-placebo group). Frequent follow-up allowed ongoing risk reduction counseling, adherence support, and testing for HIV infection and other STIs that may have influenced adherence. Limitations include the study population being "at risk" for HIV infection rather than necessarily at "high risk" on the basis of self-reported behavior; self-assessed HIV risk may have influenced adherence to study drugs. The study regimens consisted of 3 pills (2 more than the standard PrEP regimen of TDF-FTC) and used 300-mg daily dosing of MVC, although the drug is approved for HIV treatment with twice-daily dosing. Finally, the study was not powered to detect differences in specific adverse events, was not designed to assess efficacy, and had follow-up limited to 48 weeks.
In summary, we found that MVC-containing PrEP regimens were generally safe and well-tolerated compared with the standard-of-care regimen of TDF-FTC in U.S. women who were at risk for HIV infection. Study drugs were taken by more than 60% of women, as demonstrated by detectable drug concentrations in available plasma samples, and in a subset analysis, more than 90% had drug concentrations historically associated with high levels of adherence and protection against HIV acquisition (30) . Although no HIV infections occurred in this study, it was not designed to assess efficacy. Given concerns about suboptimal TFV levels in the female genital tract, additional PrEP choices are needed. Maraviroc-containing oral PrEP regimens, with demonstrated safety and tolerability similar to that of TDF-FTC, may warrant further study in fully powered efficacy studies for HIV PrEP. 35 (19) 2 (25) 2 (13) 5 (24) 2 (11) 1 (20) 3 (19) 10 (31) 3 (20) 3 (20) 2 ( 1 (13) 1 (7) 4 (19) 1 ( IQR = interquartile range; NA = not applicable. * 1 participant had 2 occurrences of suicidal ideation. † 1 participant had 2 events. ‡ The study investigators assessed the relationship of adverse event to study drug. § These events were predetermined to be of interest given prior reports of toxicities associated with the study medications. All were grade 2 except for 2 occurrences of grade 3 hypophosphatemia and 1 occurrence of grade 3 weight loss.
